Literature DB >> 30835706

SF-36 scores predict postoperative delirium after surgery for cervical spondylotic myelopathy.

Kyohei Kin, Takao Yasuhara, Yousuke Tomita, Michiari Umakoshi, Jun Morimoto, Isao Date.   

Abstract

OBJECTIVECervical spondylotic myelopathy (CSM) is one of the most common causes of spinal cord dysfunction. Surgery for CSM is generally effective, but postoperative delirium is a potential complication. Although there have been some studies that investigated postoperative delirium after spine surgery, no useful tool for identifying high-risk patients has been established, and it is unknown if 36-Item Short Form Health Survey (SF-36) scores can predict postoperative delirium. The objective of this study was to evaluate the correlation between preoperative SF-36 scores and postoperative delirium after surgery for CSM.METHODSSixty-seven patients who underwent surgery for CSM at the authors' institution were enrolled in this study. Medical records of these patients were retrospectively reviewed. Patient background, preoperative laboratory data, preoperative SF-36 scores, the preoperative Japanese Orthopaedic Association (JOA) score for the evaluation of cervical myelopathy, and perioperative factors were selected as potential risk factors for postoperative delirium. These factors were evaluated using univariable and multivariable logistic regression analysis.RESULTSTen patients were diagnosed with postoperative delirium. Univariable analysis revealed that the physical functioning score (p = 0.01), general health perception score (p < 0.01), and vitality score (p < 0.01) of the SF-36 were significantly lower in patients with postoperative delirium than in those without. The total number of medications was significantly higher in the delirium group compared with the no-delirium group (p = 0.02). In contrast, there were no significant differences between the delirium group and the no-delirium group in cervical JOA scores (p = 0.20). Multivariable analysis revealed that a low general health perception score was an independent risk factor for postoperative delirium (p = 0.02; odds ratio 0.810, 95% confidence interval 0.684-0.960).CONCLUSIONSSome of the SF-36 scores were significantly lower in patients with postoperative delirium than in those without. In particular, the general health perception score was independently correlated with postoperative delirium. SF-36 scores could help identify patients at high risk for postoperative delirium and aid in the development of prevention strategies.

Entities:  

Keywords:  CCI = Charlson Comorbidity Index; CSM = cervical spondylotic myelopathy; ICU = intensive care unit; JOA = Japanese Orthopaedic Association; QOL = quality of life; SF-36 = 36-Item Short Form Health Survey; Short-Form 36; cervical; delirium; myelopathy; postoperative; spine

Year:  2019        PMID: 30835706     DOI: 10.3171/2018.11.SPINE181031

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Prevalence and risk factors of postoperative delirium after spinal surgery: a meta-analysis.

Authors:  Hua Gao; Hui-Juan Ma; Ying-Jia Li; Ci Yin; Zheng Li
Journal:  J Orthop Surg Res       Date:  2020-04-09       Impact factor: 2.359

2.  Clinical Efficacy and Safety of Anterior Cervical Decompression versus Segmental Fusion and Posterior Expansive Canal Plasty in the Treatment of Multilevel Cervical Spondylotic Myelopathy.

Authors:  Chen Xia; Fangfang Shi; Chuyong Chen; Jun Lv; Qi Chen
Journal:  J Healthc Eng       Date:  2022-04-11       Impact factor: 3.822

3.  Incidence and Risk Factors for Postoperative Delirium in Patients Undergoing Spine Surgery: A Systematic Review and Meta-Analysis.

Authors:  Xinjie Wu; Wei Sun; Mingsheng Tan
Journal:  Biomed Res Int       Date:  2019-11-26       Impact factor: 3.411

4.  Preoperative risk factors for delirium in patients aged ≥75 years undergoing spinal surgery: a retrospective study.

Authors:  Hiroaki Onuma; Hiroyuki Inose; Toshitaka Yoshii; Takashi Hirai; Masato Yuasa; Shigenori Kawabata; Atsushi Okawa
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.